Overview
1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
Current Duke Appointments & Affiliations
George Barth Geller Distinguished Professor for Research in Cancer
·
2005 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
1997 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1974 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.
Journal article J Cachexia Sarcopenia Muscle · August 2026 BACKGROUND: Cachexia, a complex multifactorial syndrome characterized by loss of skeletal muscle mass, is common in cancer and impacts treatment response, quality of life (QoL) and survival. No effective therapy is currently available. This report summariz ... Full text Link to item CiteAlirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text CiteAbstract 6638: Real-World evidence of eflapegrastim (efla) usage in patients with gastrointestinal (GI) malignancies.
Conference Cancer Research · April 3, 2026 AbstractBackground:Long-acting granulocyte colony-stimulating factors (GCSFs) such as efla and pegfilgrastim (peg) are routinel ... Full text CiteRecent Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2032A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Durvalumab plus Chemotherapy Prior to Surgery Followed by Durvalumab Post-surgery Versus Placebo plus Chemotherapy Prior to Surgery Followed by Placebo Post surgery
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2019 - 2026Alliance/NCORP Parent - Non Federal
Clinical TrialPrincipal Investigator · Awarded by Alliance NCTN Foundation · 2020 - 2026View All Grants
Education
Ohio State University ·
1974
M.D.